Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries

Andrew E Moran; Margaret Farrell; Danielle Cazabon; Swagata Kumar Sahoo; Doris Mugrditchian; Anirudh Pidugu; Carlos Chivardi; Magdalena Walbaum; Senait Alemayehu; Wanrudee Isaranuwatchai; Chaisiri Ankurawaranon; Sohel R Choudhury; Sarah J Pickersgill; David A Watkins; Muhammad Jami Husain; Krishna D Rao; Kunihiro Matsushita; Matti Marklund; Brian Hutchinson; Rachel Nugent; Deliana Kostova; Renu Garg

doi:10.26633/RPSP.2022.140

Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries

Andrew E Moran, Margaret Farrell, Danielle Cazabon, Swagata Kumar Sahoo, Doris Mugrditchian, Anirudh Pidugu, Carlos Chivardi, Magdalena Walbaum, Senait Alemayehu, Wanrudee Isaranuwatchai, Chaisiri Ankurawaranon, Sohel R Choudhury, Sarah J Pickersgill, David A Watkins, Muhammad Jami Husain, Krishna D Rao, Kunihiro Matsushita, Matti Marklund, Brian Hutchinson, Rachel NugentDeliana Kostova, Renu Garg

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in low- and middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average <US$ 5 per patient per year in the public sector. This health economic evidence will make a compelling case for government ownership and financial support for national scale hypertension control programs.

Original language	English
Article number	e140
Number of pages	10
Journal	Pan American Journal of Public Health / Revista Panamericana de Salud Pública
Volume	46
DOIs	https://doi.org/10.26633/RPSP.2022.140
Publication status	Published - 17 Aug 2022

Access to Document

10.26633/RPSP.2022.140Licence: CC BY-NC-ND

v46e1402022Final published version, 320 KBLicence: CC BY-NC-ND

Cite this

Moran, A. E., Farrell, M., Cazabon, D., Sahoo, S. K., Mugrditchian, D., Pidugu, A., Chivardi, C., Walbaum, M., Alemayehu, S., Isaranuwatchai, W., Ankurawaranon, C., Choudhury, S. R., Pickersgill, S. J., Watkins, D. A., Husain, M. J., Rao, K. D., Matsushita, K., Marklund, M., Hutchinson, B., ... Garg, R. (2022). Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries. Pan American Journal of Public Health / Revista Panamericana de Salud Pública, 46, Article e140. https://doi.org/10.26633/RPSP.2022.140

@article{78f711200fbb4321a43c1700f104c1f3,

title = "Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries",

abstract = "Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in low- and middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average ",

author = "Moran, {Andrew E} and Margaret Farrell and Danielle Cazabon and Sahoo, {Swagata Kumar} and Doris Mugrditchian and Anirudh Pidugu and Carlos Chivardi and Magdalena Walbaum and Senait Alemayehu and Wanrudee Isaranuwatchai and Chaisiri Ankurawaranon and Choudhury, {Sohel R} and Pickersgill, {Sarah J} and Watkins, {David A} and Husain, {Muhammad Jami} and Rao, {Krishna D} and Kunihiro Matsushita and Matti Marklund and Brian Hutchinson and Rachel Nugent and Deliana Kostova and Renu Garg",

year = "2022",

month = aug,

day = "17",

doi = "10.26633/RPSP.2022.140",

language = "English",

volume = "46",

journal = "Pan American Journal of Public Health / Revista Panamericana de Salud P{\'u}blica",

issn = "1020-4989",

publisher = "Pan American Health Organization",

}

Moran, AE, Farrell, M, Cazabon, D, Sahoo, SK, Mugrditchian, D, Pidugu, A, Chivardi, C, Walbaum, M, Alemayehu, S, Isaranuwatchai, W, Ankurawaranon, C, Choudhury, SR, Pickersgill, SJ, Watkins, DA, Husain, MJ, Rao, KD, Matsushita, K, Marklund, M, Hutchinson, B, Nugent, R, Kostova, D & Garg, R 2022, 'Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries', Pan American Journal of Public Health / Revista Panamericana de Salud Pública, vol. 46, e140. https://doi.org/10.26633/RPSP.2022.140

Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries. / Moran, Andrew E; Farrell, Margaret; Cazabon, Danielle et al.
In: Pan American Journal of Public Health / Revista Panamericana de Salud Pública, Vol. 46, e140, 17.08.2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries

AU - Moran, Andrew E

AU - Farrell, Margaret

AU - Cazabon, Danielle

AU - Sahoo, Swagata Kumar

AU - Mugrditchian, Doris

AU - Pidugu, Anirudh

AU - Chivardi, Carlos

AU - Walbaum, Magdalena

AU - Alemayehu, Senait

AU - Isaranuwatchai, Wanrudee

AU - Ankurawaranon, Chaisiri

AU - Choudhury, Sohel R

AU - Pickersgill, Sarah J

AU - Watkins, David A

AU - Husain, Muhammad Jami

AU - Rao, Krishna D

AU - Matsushita, Kunihiro

AU - Marklund, Matti

AU - Hutchinson, Brian

AU - Nugent, Rachel

AU - Kostova, Deliana

AU - Garg, Renu

PY - 2022/8/17

Y1 - 2022/8/17

N2 - Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in low- and middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average

AB - Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in low- and middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average

U2 - 10.26633/RPSP.2022.140

DO - 10.26633/RPSP.2022.140

M3 - Article

C2 - 36071923

SN - 1020-4989

VL - 46

JO - Pan American Journal of Public Health / Revista Panamericana de Salud Pública

JF - Pan American Journal of Public Health / Revista Panamericana de Salud Pública

M1 - e140

ER -